≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease

DOID Endpoint Browser PheWeb

E4_HYPERURI

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E79.0
  • Cause of death: ICD-10 — E79.0

2 out of 7 registries used, show all original rules.

162

4. Check minimum number of events

None

162

5. Include endpoints

None

162

6. Filter based on genotype QC (FinnGen only)

162

Control definitions (FinnGen only)

Control exclude
E4_METABOLIA

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E79
Name in latin
Hyperurichaemia sine symptomatibus arthritidis inflammatoriae sive morbi tophacei

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1098 486 606
Only index persons 956 413 543
Unadjusted period prevalence (%)
Whole population 0.02 0.01 0.02
Only index persons 0.02 0.02 0.02
Median age at first event (years)
Whole population 67.61 70.73 65.06
Only index persons 65.92 68.15 64.22

-FinnGen-

Key figures

All Female Male
Number of individuals 162 58 104
Unadjusted period prevalence (%) 0.04 0.02 0.05
Median age at first event (years) 65.33 62.56 66.88

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
149
Matched controls
1489
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E79.0
ICD-10 Finland
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
+∞
215.4
149
*
M04AA01
ATC
allopurinol; systemic
15.4
46.4
92
141
M10.9
ICD-10 Finland
Gout, unspecified
9.8
19.8
42
57
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
7.5
15.7
39
67
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
9.3
15.5
33
44
C03CA01
ATC
furosemide; systemic
4.2
15.0
76
293
M10.0
ICD-10 Finland
Idiopathic gout
15.7
14.3
23
17
H02AB06
ATC
prednisolone; systemic
3.9
13.8
99
504
212
Kela drug reimbursment
Gout
15.0
13.4
22
17
N17.9
ICD-10 Finland
Acute renal failure, unspecified
14.2
12.0
20
16
M13.9
ICD-10 Finland
Arthritis, unspecified
7.1
11.6
29
49
C10AA05
ATC
atorvastatin; oral
3.4
11.4
81
388
A46
ICD-10 Finland
Erysipelas
4.7
10.9
40
108
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
10.6
89
472
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.1
10.2
25
41
C07AB07
ATC
bisoprolol; oral
3.1
10.0
96
547
I50.9
ICD-10 Finland
Heart failure, unspecified
4.2
9.7
40
120
I10
ICD-10 Finland
Essential (primary) hypertension
3.1
9.5
108
680
J01FF01
ATC
clindamycin; systemic
3.3
9.5
59
246
205
Kela drug reimbursment
Chronic hypertension
3.1
9.5
69
324
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.3
9.4
25
46
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
9.3
36
102
P01BA02
ATC
hydroxychloroquine; oral
5.6
9.1
27
57
C08CA01
ATC
amlodipine; oral
2.9
8.9
77
399
A10BH05
ATC
linagliptin; oral
6.8
8.9
22
37
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
12.7
8.8
15
13
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
53.2
8.8
10
*
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
53.2
8.8
10
*
M04AA03
ATC
febuxostat; oral
53.2
8.8
10
*
288
Kela drug reimbursment
Febuxostat
29.5
8.6
11
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.4
8.5
22
39
R06.0
ICD-10 Finland
Dyspnoea
3.3
8.5
49
192
E86
ICD-10 Finland
Volume depletion
+∞
8.4
8
*
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
12.7
8.3
14
12
L28
ICPC
Limited function/disability (L)
3.5
8.2
41
144
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
18.5
8.2
12
7
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
18.5
8.2
12
7
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
4.2
8.2
32
91
349
Kela drug reimbursment
Febuxostat
35.5
8.2
10
*
A10BA02
ATC
metformin; oral
2.9
8.2
62
290
C10AA01
ATC
simvastatin; oral
2.8
8.1
85
484
J01DB01
ATC
cefalexin; oral
3.5
8.0
129
961
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.6
8.0
39
135
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
5.1
7.9
25
57
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.0
7.9
54
234
103
Kela drug reimbursment
Diabetes, insulin-treated
2.9
7.9
59
275
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.4
7.9
29
78
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
3.1
7.7
48
196
A07EC01
ATC
sulfasalazine; oral, rectal
5.1
7.7
24
54
C03DA01
ATC
spironolactone; oral
4.2
7.6
29
81
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
9.1
7.5
15
18
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.3
6.9
37
134
N19
ICD-10 Finland
Unspecified kidney failure
8.5
6.8
14
18
H02AB07
ATC
prednisone; oral
3.5
6.7
32
108
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
5.4
6.6
19
39
G47.3
ICD-10 Finland
Sleep apnoea
2.9
6.5
43
182
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
11.8
6.4
11
10
AN1
HP
Coronary angiography
3.5
6.3
29
95
E66.01
ICD-10 Finland
Obesity due to excess calories
5.7
6.2
17
33
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.7
6.2
48
221
A10AE05
ATC
insulin detemir; parenteral
6.0
6.2
16
29
N02BE01
ATC
paracetamol; systemic, rectal
3.4
6.2
134
1077
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
4.7
6.1
20
48
J01MA12
ATC
levofloxacin; systemic
2.8
6.1
41
176
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
5.8
6.0
16
30

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
115
356
8.69
40.19
6.1
2.6
434.2
7842.7
umol/l
1.75
105
300
60
187
4.51
18.00
5.0
2.1
18.7
23.5
%
2.37
54
159
42
109
4.85
15.68
3.3
3.3
75.2
71.7
e9/l
0.27
32
89
85
368
3.76
15.61
6.9
4.7
—
—
—
0
0
42
110
4.80
15.50
10.0
3.6
2.2
2.2
mmol/l
0.01
30
83
116
624
4.03
15.13
16.7
6.6
1.2
1.2
mmol/l
0.94
95
527
18
20
10.00
14.95
7.9
2.5
—
—
—
0
0
110
577
3.82
14.78
15.3
6.0
1.2
1.2
mmol/l
0.92
102
517
42
114
4.62
14.78
9.9
3.9
—
—
—
0
0
48
156
3.95
13.17
2.8
2.9
2.1
1.8
%
1.11
42
143
28
59
5.53
13.17
2.0
1.8
1.7
1.4
g/l
0.66
23
50
113
636
3.57
12.91
8.8
6.0
0.7
0.6
e9/l
1.39
103
559
25
49
5.85
12.67
9.2
5.1
24.6
23.7
mmol/l
0.62
20
41
113
641
3.52
12.64
9.2
6.0
0.0
0.0
e9/l
0.07
104
568
112
650
3.34
11.70
9.4
6.1
1.8
1.9
e9/l
0.24
104
587
113
662
3.34
11.56
9.3
6.1
0.2
0.2
e9/l
0.30
102
596
33
93
4.20
10.88
2.1
1.5
—
—
—
0
0
79
391
2.99
10.65
6.2
3.7
28.4
4.9
mg/mmol
2.54
64
243
78
384
2.99
10.61
5.0
3.0
6.4
7.9
mmol/l
3.11
70
309
118
730
3.27
10.58
13.7
10.1
4.7
4.0
e9/l
2.70
111
658
77
377
2.99
10.57
2.3
2.0
153.3
169.6
u/l
0.24
72
350
51
197
3.32
10.55
1.3
1.3
31.7
10.1
u/ml
0.89
18
72
78
386
2.97
10.48
10.5
3.9
7.4
7.4
ph
0.27
20
77
52
205
3.26
10.38
3.1
2.1
—
—
—
0
0
58
244
3.15
10.38
4.5
2.5
502.7
567.2
mosm/kgh2o
1.97
52
200
98
553
2.95
10.26
13.7
10.1
1.3
1.3
inr
0.05
25
148
75
367
2.94
10.23
3.4
2.8
—
—
—
0
0
26
64
4.65
10.14
8.6
3.4
—
—
—
0
0
33
98
3.97
10.10
21.8
7.1
—
—
—
0
0
75
371
2.90
9.98
4.9
3.0
146.6
34.6
mg/l
2.92
59
241
43
156
3.39
9.77
11.9
8.8
1.4
1.6
mmol/l
0.09
31
120
93
528
2.79
9.34
2.5
2.0
76.3
95.9
pmol/l
4.16
56
288
29
83
4.04
9.30
15.6
6.6
89.5
93.5
%
0.59
29
83
14
21
7.20
9.05
6.1
2.4
16.9
16.6
%
—
9
10
59
270
2.86
8.90
6.4
5.7
—
—
—
0
0
41
153
3.25
8.84
1.3
1.3
323.6
544.7
titre
0.61
11
34
79
424
2.68
8.70
9.8
5.9
—
—
—
0
0
127
872
3.11
8.50
6.4
4.1
—
—
—
0
0
64
316
2.69
8.24
3.0
2.0
4.0
3.3
mg/l
1.20
57
277
31
102
3.52
8.11
4.9
8.5
—
—
—
0
0
10
12
8.82
7.66
1.2
1.2
—
—
—
0
0
85
501
2.47
7.36
5.4
2.4
228.3
157.5
ug/l
1.02
77
458
46
202
2.78
7.33
1.5
1.3
49.2
29.3
iu/ml
0.41
17
63
30
103
3.35
7.32
3.8
5.5
0.6
0.2
%
0.87
11
37
98
625
2.44
7.01
7.4
4.6
0.0
0.0
estimate
0.00
26
118
98
626
2.43
6.97
6.0
3.6
0.0
0.0
estimate
0.00
25
119
31
112
3.19
6.96
4.0
5.2
0.7
1.2
%
0.61
11
43
11
17
6.87
6.87
5.0
1.6
—
—
—
0
0
46
212
2.63
6.61
3.2
1.7
29.4
29.2
s
0.13
46
202
98
640
2.34
6.44
6.0
3.6
0.0
0.0
estimate
0.00
24
118
66
364
2.37
6.44
5.4
3.0
0.6
0.4
e6/l
0.46
58
272
128
947
2.68
6.27
7.4
4.3
22.9
13.0
mm/h
6.38
123
866
54
277
2.42
6.15
4.1
2.6
5.5
4.3
e6/l
0.34
49
242
76
454
2.27
6.07
6.1
3.4
367.9
91.1
e6/l
0.50
62
341
32
128
2.87
5.99
3.0
2.4
3.3
7.5
ug/l
1.40
27
115
25
88
3.18
5.82
6.0
2.7
7.4
7.4
ph
—
6
9
116
841
2.34
5.61
5.8
4.3
—
3690.6
—
0
16
68
400
2.21
5.53
5.4
3.1
97.5
217.7
e6/l
0.32
58
314
26
97
3.00
5.49
2.9
5.2
0.2
0.5
%
—
5
28
62
353
2.23
5.45
5.4
3.0
—
—
—
0
0
72
436
2.17
5.42
3.2
3.3
2.3
2.4
mmol/l
0.43
65
373
29
116
2.83
5.41
6.0
3.4
—
—
—
0
0
13
30
4.62
5.40
1.1
1.0
—
—
—
0
0
59
334
2.21
5.22
2.1
1.6
18.5
20.7
nmol/l
0.55
52
281
63
367
2.17
5.18
6.5
4.0
0.0
0.0
estimate
0.00
21
117
49
259
2.28
5.10
2.2
1.6
1407.3
1192.8
nmol/l
0.84
41
197
25
96
2.90
5.01
3.8
5.6
0.0
0.0
%
—
6
30
82
534
2.08
5.00
6.7
3.5
43.4
37.1
ng/l
0.35
65
392
42
210
2.35
4.96
2.0
1.4
3.1
2.9
g/l
0.17
32
124
34
156
2.49
4.83
2.4
1.6
—
—
—
0
0
18
59
3.31
4.68
1.4
1.4
—
—
—
0
0
56
323
2.12
4.65
11.9
6.4
—
—
—
0
0
28
119
2.64
4.64
2.4
1.6
—
—
—
0
0
50
280
2.14
4.45
6.4
3.8
—
—
—
0
0
82
553
1.98
4.37
18.0
9.5
0.0
0.0
e9/l
0.50
73
458
13
36
3.84
4.30
5.5
2.1
8.5
8.1
kpa
0.20
13
30
11
27
4.30
4.23
5.7
2.2
—
—
—
0
0
12
32
3.97
4.17
1.4
2.0
—
—
—
0
0
17
58
3.16
4.15
1.5
1.3
—
—
—
0
0
9
14
6.73
4.04
3.1
1.1
89.8
88.0
%
—
9
14
24
103
2.56
3.89
8.0
3.7
1.2
1.2
mmol/l
0.05
24
93
28
130
2.39
3.85
2.4
1.6
—
—
—
0
0
15
50
3.20
3.80
1.4
1.2
36.0
36.8
g/l
0.17
15
43
9
17
5.54
3.56
2.4
1.4
—
—
—
0
0
9
17
5.54
3.56
2.4
1.4
—
—
—
0
0
9
17
5.54
3.56
2.4
1.4
—
—
—
0
0
9
17
5.54
3.56
2.4
1.4
—
—
—
0
0
30
151
2.21
3.43
2.3
3.3
10.1
8.9
umol/l
0.15
25
132
9
18
5.23
3.42
3.0
1.4
1.8
1.6
mmol/l
—
9
18
10
27
3.88
3.41
3.9
2.5
0.8
0.8
nmol/l
—
5
19
10
27
3.88
3.41
3.9
3.8
—
—
—
0
0
7
10
7.26
3.40
1.3
1.2
—
—
—
0
0
24
110
2.39
3.39
3.6
3.4
471.6
193.8
ng/l
1.11
24
98
9
19
4.95
3.29
5.1
4.1
—
—
—
0
0
9
21
4.47
3.04
1.4
1.5
—
—
—
0
0
12
40
3.16
3.04
3.2
3.3
0.3
0.2
g/l
—
5
15
29
152
2.11
2.99
1.2
1.2
—
—
—
0
0
145
1274
2.32
2.82
35.4
14.8
26.5
24.4
mg/l
0.37
137
1021
12
42
3.01
2.81
2.5
1.7
—
—
—
0
0
59
401
1.74
2.77
3.6
2.5
—
—
—
0
0
5
6
8.55
2.77
1.4
1.0
—
—
—
0
0
6
10
6.18
2.72
2.0
2.6
—
—
—
0
0
6
10
6.18
2.72
1.0
1.3
—
—
—
0
0
7
15
4.82
2.62
5.3
1.8
72.1
64.1
%
—
7
15
29
161
1.98
2.57
2.5
1.7
—
—
—
0
0
6
11
5.62
2.56
1.3
1.4
—
—
—
0
0
6
11
5.62
2.56
1.0
1.5
—
—
—
0
0
60
422
1.67
2.44
5.6
3.5
—
—
—
0
0
6
12
5.15
2.42
1.5
1.6
—
—
—
0
0
46
302
1.73
2.40
7.7
3.7
89.2
89.6
%
0.03
46
295
112
926
1.68
2.38
5.9
4.1
—
—
—
0
0
18
86
2.23
2.33
1.8
1.5
—
—
—
0
0
37
231
1.78
2.29
1.3
1.2
0.6
2.0
u/ml
0.75
13
57
32
192
1.83
2.25
1.3
1.2
—
—
—
0
0
41
267
1.72
2.19
2.0
1.8
499.3
427.6
pmol/l
0.63
35
222
8
25
3.31
2.12
1.0
1.9
—
—
—
0
0
6
15
4.11
2.06
4.3
2.1
—
—
—
0
0
9
32
2.92
2.03
1.1
1.2
—
—
—
0
0
109
916
1.58
1.97
5.0
3.7
15.2
14.9
pmol/l
0.58
98
815
8
27
3.06
1.96
3.8
1.5
—
—
—
0
0
40
269
1.65
1.89
3.7
1.7
1.4
1.3
mg/l
0.10
31
211
129
1135
1.67
1.86
5.9
4.5
2.0
1.9
mu/l
0.19
123
1007
6
17
3.62
1.85
1.7
1.6
—
—
—
0
0
5
12
4.26
1.83
1.0
1.0
—
—
—
0
0
9
35
2.66
1.83
1.7
1.5
—
—
—
0
0
14
67
2.19
1.82
25.4
16.2
—
—
—
0
0
9
36
2.59
1.77
1.7
1.2
—
—
—
0
0
6
18
3.42
1.76
1.3
1.2
—
—
—
0
0
19
104
1.94
1.76
5.8
3.9
—
—
—
0
0
14
68
2.16
1.76
5.0
2.7
—
—
—
0
0
5
13
3.93
1.73
1.0
1.2
—
—
—
0
0
49
355
1.55
1.69
5.1
3.1
—
—
—
0
0
7
25
2.88
1.67
4.4
2.2
6.7
7.9
mmol/l
—
7
25
5
14
3.65
1.62
1.0
1.1
—
—
—
0
0
26
162
1.72
1.62
1.7
1.7
—
—
—
0
0
145
1332
1.84
1.60
34.5
13.8
—
—
—
0
0
6
20
3.07
1.59
3.3
2.5
3.6
4.5
e9/l
—
6
20
5
15
3.40
1.53
1.0
1.0
—
—
—
0
0
7
27
2.66
1.53
4.4
2.1
1.2
1.9
mmol/l
—
7
27
19
111
1.81
1.47
1.4
1.4
—
—
—
0
0
19
111
1.81
1.47
1.4
1.4
—
—
—
0
0
125
1115
1.53
1.46
32.9
15.7
38.0
39.8
%
0.83
72
756
5
16
3.19
1.45
1.0
1.2
—
—
—
0
0
6
22
2.79
1.45
3.5
3.5
53.3
56.3
%
—
6
22
9
42
2.21
1.36
5.4
3.4
—
—
—
0
0
5
18
2.83
1.29
1.4
1.3
—
—
nmol/l
—
0
0
12
63
1.98
1.26
1.2
1.2
—
—
—
0
0
8
37
2.22
1.23
14.1
13.5
—
—
—
0
0
8
38
2.16
1.20
1.3
1.2
—
—
—
0
0
6
26
2.36
1.20
1.3
1.1
—
—
—
0
0
6
26
2.36
1.20
1.2
1.2
—
—
—
0
0
12
69
1.80
0.99
1.8
2.3
—
—
—
0
0
17
109
1.63
0.98
1.6
1.4
—
—
—
0
0
11
64
1.77
0.88
1.0
1.3
—
—
—
0
0
138
1302
1.40
0.78
6.9
5.0
2.5
2.7
mmol/l
2.51
131
1173
130
1216
1.35
0.77
10.1
5.8
44.1
40.0
mmol/mol
3.37
124
1118
18
125
1.50
0.76
6.5
3.6
—
—
—
0
0
135
1273
1.36
0.72
6.3
4.5
4.3
4.6
mmol/l
1.87
127
1158
9
58
1.58
0.71
6.9
3.1
—
—
—
0
0
11
69
1.64
0.70
1.6
2.8
—
—
—
0
0
134
1266
1.34
0.68
6.2
4.4
1.3
1.4
mmol/l
3.97
126
1140
8
51
1.60
0.61
4.1
13.9
1.3
1.7
%
—
8
46
129
1226
1.26
0.52
5.8
4.0
1.8
1.3
mmol/l
7.44
120
1098
7
51
1.39
0.44
3.7
1.5
—
—
—
0
0
11
78
1.44
0.44
1.0
1.2
—
—
—
0
0
5
31
1.63
0.43
8.8
3.5
—
—
—
0
0
71
648
1.17
0.41
4.2
5.3
2.6
2.8
ug/l
0.12
63
579
57
514
1.17
0.38
1.8
2.1
—
—
—
0
0
38
331
1.19
0.38
1.6
1.3
—
—
—
0
0
7
100
0.69
0.31
3.0
3.0
—
—
—
0
0
130
1261
1.16
0.26
6.3
4.8
6.5
6.0
mmol/l
2.69
121
1141
38
420
0.88
0.26
3.6
2.8
—
—
—
0
0
10
78
1.30
0.25
1.1
1.3
—
30.6
—
0
9
18
154
1.19
0.22
4.6
4.7
3.2
73.2
ug/l
0.79
13
132
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
1.5
—
0
5
0
14
0.00
0.20
0.0
1.1
—
6.4
—
0
6
6
51
1.18
0.19
2.7
14.0
0.7
0.9
%
—
6
45
11
92
1.21
0.16
2.1
2.3
—
5.4
—
0
6
107
1043
1.08
0.13
49.7
20.0
329.3
332.4
g/l
2.69
107
1037
7
63
1.12
0.08
2.3
3.6
15.1
1867.2
u/ml
—
7
52
12
112
1.08
0.03
1.3
1.4
—
—
—
0
0
17
174
0.97
0.00
1.3
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
7.4
—
—
—
0
0
0
5
0.00
0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
0.00
0.0
17.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
18.3
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
27.9
—
0
9
0
6
0.00
0.00
0.0
7.0
—
863.0
—
0
6
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
9.3
—
0.7
—
0
6
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
5.3
—
651.0
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_HYPERURI and mortality.

Females

Parameter HR [95% CI] p-value
E4_HYPERURI 2.552 [1.94, 3.35] < 0.001
Birth year 0.993 [0.98, 1.0] 0.157

During the follow-up period (1.1.1998 — 31.12.2019), 188 out of 407 females with E4_HYPERURI died.

Males

Parameter HR [95% CI] p-value
E4_HYPERURI 2.743 [1.91, 3.95] < 0.001
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 494 males with E4_HYPERURI died.

Mortality risk

Mortality risk for people of age

years, who have E4_HYPERURI.

N-year risk Females Males
1 0.153% 0.478%
5 1.103% 2.974%
10 3.035% 7.543%
15 5.976% 13.46%
20 10.95% 22.07%

Relationships between endpoints

↥

Index endpoint: E4_HYPERURI – Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data